Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) have received a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $45.55.

A number of equities analysts have issued reports on the stock. Chardan Capital restated a “buy” rating and issued a $53.00 price objective on shares of Outlook Therapeutics in a research report on Friday, August 16th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a research report on Thursday, August 15th.

Outlook Therapeutics Stock Down 0.8 %

Outlook Therapeutics stock opened at $7.10 on Friday. The company has a market capitalization of $166.21 million, a PE ratio of -0.62 and a beta of 0.71. The firm has a fifty day simple moving average of $7.68 and a two-hundred day simple moving average of $8.05. Outlook Therapeutics has a twelve month low of $4.00 and a twelve month high of $29.20.

Institutional Investors Weigh In On Outlook Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Great Point Partners LLC lifted its stake in shares of Outlook Therapeutics by 15.0% in the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after buying an additional 221,510 shares in the last quarter. Rosalind Advisors Inc. lifted its stake in shares of Outlook Therapeutics by 44.3% in the second quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock worth $3,321,000 after buying an additional 138,225 shares in the last quarter. LVW Advisors LLC bought a new position in shares of Outlook Therapeutics in the second quarter worth approximately $352,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Outlook Therapeutics in the second quarter worth approximately $303,000. Finally, Squarepoint Ops LLC bought a new position in shares of Outlook Therapeutics in the second quarter worth approximately $232,000. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.